EQUITY IN NON-MARKETABLE SECURITIES OF AFFILIATED ENTITY (Details Narrative) - USD ($) |
8 Months Ended | 12 Months Ended | |
|---|---|---|---|
Jun. 30, 2026 |
Oct. 31, 2025 |
Oct. 31, 2024 |
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
| Equity in non-marketable securities | $ 145,000 | ||
| Aggregate cash consideration description | Exotropin’s Limited Liability Company Agreement (as amended to date, the “LLC Agreement”) relating to the Membership Units (collectively, the “Membership Interests”), for the aggregate cash consideration of $2,788,000 (the “Purchase Price”). The Parties agreed to allocate the Purchase Price as follows: $376,000 to the Company in respect of the Company’s Membership Interests; $1,206,000 to Greyt in respect of Greyt’s Membership Interests; and $1,206,000 to Skycrest in respect of Skycrest’s Membership Interests (the foregoing amounts allocated to each of the Sellers, an “Allocated Purchase Price”). | ||
| Gain from sale of Exotropin interests | $ 390,000 | ||
| Proceeds from sale of interests in Exotropin | 376,000 | ||
| Reduction of previously recorded liabilities | 14,000 | ||
| Commissions | (678,000) | (521,000) | $ (734,000) |
| Sales representative agreement [Member] | |||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
| Commissions | $ 0 | $ 61,000 | $ 87,000 |